SCHEMBL5536696

SCHEMBL5536696

Cc1ccc(/C=C/CO[C]=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RELA Q04206 1/20 0.41
CA1 P00915 1/20 0.41
NFE2L2 Q16236 2/20 0.39
FBP1 P09467 1/20 0.39
CYP2A6 P11509 1/20 0.39
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 1/20 0.38
GRIK1 P39086 1/20 0.38
GRIK2 Q13002 1/20 0.38
KMT2A Q03164 1/20 0.38
IDO1 P14902 2/20 0.36
FOS P01100 1/20 0.36
JUN P05412 1/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536698 1.00 RELA (0.41) RELACA1NFE2L2FBP1CYP2A6
SCHEMBL5545965 0.82 GSK3B (0.49) RELANFE2L2FBP1CYP2A6RAB9A
SCHEMBL5545961 0.82 GSK3B (0.49) RELANFE2L2FBP1CYP2A6RAB9A
SCHEMBL5541067 0.81 HSD11B1 (0.41) NFE2L2FBP1GRIK1GRIK2IDO1
SCHEMBL5544290 0.81 CYP1A2 (0.41) NFE2L2FBP1GRIK1GRIK2IDO1
SCHEMBL5544293 0.81 CYP1A2 (0.41) NFE2L2FBP1GRIK1GRIK2IDO1
SCHEMBL5541069 0.81 HSD11B1 (0.41) NFE2L2FBP1GRIK1GRIK2IDO1
SCHEMBL5547901 0.81 GRIK1 (0.39) RAB9ANPC1SMN1; SMN2MAPTGRIK1
SCHEMBL3793245 0.81 APP (0.42) RELARAB9ANPC1MAPTKMT2A
SCHEMBL5547894 0.81 GRIK1 (0.39) RAB9ANPC1SMN1; SMN2MAPTGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 RELA 998/4885CA1 3493/4885NFE2L2 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.